Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience

Immunology and Microbiology

• Acute Graft Versus Host Disease 50%
• Chronic Graft Versus Host Disease 100%
• Cyclophosphamide 50%
• Graft-Versus-Host Disease 50%
• Mortality Rate 50%
• Myeloid 50%
• Progression Free Survival 50%
• Survival Rate 50%
• Tacrolimus 50%
• Transplant Procedure 50%

Keyphrases

• Hematopoietic Transplantation 90%
• Transplant-related Mortality 9%

Medicine and Dentistry

• Polymacon 50%